Novel pharmacological targets for the treatment of Parkinson's disease.
about
Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like proteinThe A(2A)-adenosine receptor: a GPCR with unique features?The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonistComparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptorsEmerging preclinical pharmacological targets for Parkinson's diseaseNeuropharmacological Potential of Gastrodia elata Blume and Its ComponentsMechanisms and therapeutic applications of electromagnetic therapy in Parkinson's diseaseAdvances in neuroprotective ingredients of medicinal herbs by using cellular and animal models of Parkinson's diseaseS-nitrosylation of Drp1 links excessive mitochondrial fission to neuronal injury in neurodegenerationDopamine agonists in Parkinson's diseaseA synopsis on the role of tyrosine hydroxylase in Parkinson's diseaseIdentification of zebrafish A2 adenosine receptors and expression in developing embryosExtracellular nucleotide and nucleoside signaling in vascular and blood diseaseBaicalein antagonizes rotenone-induced apoptosis in dopaminergic SH-SY5Y cells related to Parkinsonism.Xanthines as adenosine receptor antagonists.Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease.Radiosynthesis and evaluation of an 18F-labeled positron emission tomography (PET) radioligand for metabotropic glutamate receptor subtype 4 (mGlu4).Transient elevation of adult hippocampal neurogenesis after dopamine depletion.Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu₄.Adenosinergic depression of glutamatergic transmission in the entorhinal cortex of juvenile rats via reduction of glutamate release probability and the number of releasable vesiclesFine-tuning serotonin2c receptor function in the brain: molecular and functional implicationsNicotine and Parkinson's disease: implications for therapy.Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction.Potent Protection Against MPP(+)-Induced Neurotoxicity via Activating Transcription Factor MEF2D by a Novel Derivative of Naturally Occurring Danshensu/Tetramethylpyrazine.Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modulator of the dopaminergic system: relevance to drugs of abuse and pathology.Curcumin and neurodegenerative diseases.MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease.Death in the substantia nigra: a motor tragedy.Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease.Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside.Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humansIrregular gastrointestinal drug absorption in Parkinson's disease.Antiparkinson prodrugs.Progress in neuroprotection in Parkinson's disease.Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?Iron Chelators as Potential Therapeutic Agents for Parkinson's DiseaseFunctional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
P2860
Q24336889-F14A2F39-DA59-4B7A-A1D1-CA5BBBD1685AQ24653743-74BB7252-A35F-4F20-840D-5A8523D90BB7Q24654563-4EEB39D9-82A8-4DA9-BE59-B3003A1602FCQ24657515-6A5C4C99-21C4-4A07-8879-46B4C284C2E3Q26764724-C14CBC70-5163-4D33-A5A8-66E18CB11D62Q26778823-C42E0853-AC83-4D7C-B1DD-C98FA4568CFAQ26782971-CA8631BD-206A-45FF-BCB1-83BD211B7CBCQ27023467-36E79E4D-E74F-4AA9-B98C-7DBEB56089AAQ27694603-407AD706-C803-4FAD-BF8A-A7D574444C97Q28276692-6AEF001C-2BCA-487E-A1D7-506823A7D2D3Q28830946-B1915DD5-357F-4A0B-882F-0959BB425FF1Q30436906-B0EC1086-F12B-4B44-AFF7-62F99372BB3AQ34047834-8F3D8B75-CA3C-4F98-AA3E-EBC2F5A71A27Q34134659-3BCFA6A0-D54F-4750-B2D6-FA0EA7B7BDD8Q34139398-94C5BD3C-D1F8-49DB-820E-4A34B69C68BCQ34183010-68F9F717-D3D4-4B4C-8F30-39A59C9A52D8Q34503368-25568718-AD96-4C8C-829E-80FBD36B29FFQ34506035-E08266C5-B038-40EF-8EDA-2911B16FA74DQ34589616-94BD1C93-3EFD-4196-884F-87290450441FQ34610593-93D02940-86B9-479B-A4C6-58C6684DB6C1Q34673489-E9FEEF21-BE89-4D60-8DBD-437559013FDDQ34685689-D1F7F8D6-0B08-4EDC-8559-1A87976561A6Q35072763-7D448B38-DE00-4548-A307-48063ACD942EQ35601652-34D04FE3-8DD3-4123-9A22-1D504B4B59F8Q35708874-70251CA2-50F1-4554-98CB-DCC91F4877D5Q36045416-520A5298-06F0-4143-AB4C-1E2F3D52E858Q36298388-A859FD81-9ADA-4223-B247-CE524D3F736BQ36497025-F08028C1-C4CD-46F5-999B-AAA74767F37EQ36625852-5B3CD5A8-2C90-4C23-A900-6736C6E8E60DQ36804513-940F5A19-4CD5-4A28-BF4D-E9F60B7573CFQ36847262-AE83D3CA-95FD-4EF3-BE64-1B8EFA13B8F8Q36883772-A6137098-945F-4656-BFFF-E5978E11E8CFQ37021321-3031C425-1737-46FD-9AF6-8CC0C0F5C9DFQ37022293-EBDD5B8D-D834-46B2-8873-23C7E8A8C90CQ37076343-FFF50781-F9FB-4E1A-A50F-3387AAEA23C7Q37079678-B3A56BBC-71AB-4E01-A460-13D575E68AD3Q37114112-86BABC66-86A8-489E-9544-782D0C99E5FAQ37183932-6941C132-4E01-4991-B0E1-9031B1328A1EQ37374312-3E0DDAE8-DB8B-4209-B6A3-1DBB671BB0F0Q37578490-E24D2C6A-C83F-41E5-A9B2-AD2F725E4B2D
P2860
Novel pharmacological targets for the treatment of Parkinson's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Novel pharmacological targets for the treatment of Parkinson's disease.
@ast
Novel pharmacological targets for the treatment of Parkinson's disease.
@en
type
label
Novel pharmacological targets for the treatment of Parkinson's disease.
@ast
Novel pharmacological targets for the treatment of Parkinson's disease.
@en
prefLabel
Novel pharmacological targets for the treatment of Parkinson's disease.
@ast
Novel pharmacological targets for the treatment of Parkinson's disease.
@en
P2093
P2860
P50
P356
P1476
Novel pharmacological targets for the treatment of Parkinson's disease.
@en
P2093
Bastian Hengerer
Borris Ferger
Etienne Hirsch
Giora Davidai
Graham L Collingridge
José A Obeso
Peter Jenner
Umberto Spampinato
P2860
P2888
P304
P356
10.1038/NRD2087
P50
P577
2006-10-01T00:00:00Z
P5875
P6179
1020393575